These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 25251326)

  • 1. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
    Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
    J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
    Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H; ;
    Haematologica; 2007 Feb; 92(2):191-8. PubMed ID: 17296568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
    J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hodgkin lymphoma among patients infected with HIV in post-HAART era.
    Tanaka PY; Pessoa VP; Pracchia LF; Buccheri V; Chamone DA; Calore EE
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):364-8. PubMed ID: 17562247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.
    Besson C; Lancar R; Prevot S; Brice P; Meyohas MC; Marchou B; Gabarre J; Bonnet F; Goujard C; Lambotte O; Boué F; Mounier N; Partisani M; Raffi F; Costello R; Hendel-Chavez H; Algarte-Genin M; Trabelsi S; Marchand L; Raphael M; Taoufik Y; Costagliola D
    Clin Infect Dis; 2015 Nov; 61(9):1469-75. PubMed ID: 26223997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
    Russell J; Collins A; Fowler A; Karanth M; Saha C; Docherty S; Padayatty J; Maw K; Lentell I; Cooke L; Hodson A; Shah N; Sadullah S; Grigoropoulos N; Qian W; Kirkwood AA; Uttenthal BJ; Johnson P; Follows GA
    Ann Hematol; 2021 Apr; 100(4):1049-1058. PubMed ID: 33641019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen.
    Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H
    Leuk Lymphoma; 2009 Oct; 50(10):1718-20. PubMed ID: 19757300
    [No Abstract]   [Full Text] [Related]  

  • 10. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
    Cheung MC; Hicks LK; Leitch HA
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):E22-5. PubMed ID: 20371439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
    Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
    Bauer K; Skoetz N; Monsef I; Engert A; Brillant C
    Cochrane Database Syst Rev; 2011 Aug; (8):CD007941. PubMed ID: 21833963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
    J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
    Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.